The APOE rs429358 and rs7412 polymorphisms were mainly associated with LDL-C and plasma total antioxidant capacity (T-AOC) levels ( p C) was related to fluvastatin pharmacokinetics in Chinese populations. SNPs in the HTR3B and HTR7 genes were significantly associated with the myalgia score and may affect the development of myalgia in statin-treated patients. To ensure the T2DM treatment effect, genetic testing was recommended to patients before medication administration. Statins are a common prescription medication for cholesterol reduction, and several intervention trials with statins have demonstrated the beneficial effect of lowering LDL-C in both primary and secondary CVD prevention, especially in subjects with T2DM. Therefore, the diagnosis and treatment of dyslipidemia is a cornerstone of diabetes mellitus management. Total cholesterol, LDL-C, triglyceride and small dense LDL-C (sdLDL-C) levels were all significantly higher in diabetes patients than in nondiabetic individuals, and the elevation of serum sdLDL-C in patients with sustained hypertension suggests the establishment of atherogenic complications among diabetes patients. Mean 10-year follow-up data in nondiabetic first-degree relatives (FDR) of consecutive patients with T2DM 30–70 years old showed that a higher LDL-C level was significantly associated with a higher risk of T2DM in high-risk individuals in Iran. Pattern B consists of LDL-3 through LDL-7, which known as small dense LDL (sdLDL), and different LDL subfractions vary in their risk profiles. Pattern A consists of LDL-1 and LDL-2 subfractions, which named larger buoyant LDL (lbLDL). Many previous studies have shown that LDL phenotype may be divided into Pattern A and Pattern B according to particle size or density distributions, by a variety of laboratory methods measure, including analytical ultracentrifugation, density ultracentrifugation by vertical auto profile (VAP), segmented gradient gel electrophoresis (sGGE), tube gel electrophoresis (TGE), nuclear magnetic resonance (NMR), or ion mobility (IM). Low-density lipoprotein cholesterol (LDL-C) is a major target for CVD prevention, and the UK Prospective Diabetes Study (UKPDS) demonstrated that LDL-C is a strong CVD risk factor in subjects with T2DM.
Therefore, T2DM is a powerful cardiovascular disease (CVD) risk factor. Cerebral infarction in people with T2DM exhibits a different clinical pattern compared with that in patients without T2DM. T2DM is associated with microvascular and macrovascular complications that lead to cardiovascular or cerebrovascular issues. According to 2014 epidemiological data, approximately 8.3% of the world adult population has primary type 2 diabetes mellitus (T2DM).
Combined multigene screening before therapy and LDL-C and sdLDL-C detection before and after therapy could better assist T2DM treatment.ĭiabetes mellitus is a metabolic disorder characterized by consistently elevated blood glucose. And the expression of LDL-C and sdLDL-C was consistent with the T2DM disease course. Gene polymorphisms related to pharmacotherapy were common in Chinese T2DM patients. After pharmacotherapy, the coincidence rates of decreases in LDL-C and sdLDL-C levels were 88.35% (311/352) and 84.09% (296/352), consistent with patients in remission. LDL-C and sdLDL-C were detected before and after treatment, sdLDL mainly existed in T2DM patients, and T2DM patients had higher mean levels of sdLDL-C than healthy people.
Genetic polymorphisms associated with T2DM and statin effects in pretreatment patients were detected, then results showed that all 11 genes had heterozygous mutation, and 7 genes had homozygous mutation in 352 T2DM patients, more specifically reflected that these gene polymorphisms were common in Chinese T2DM patients. LDL-C and sdLDL-C were detected in 352 T2DM patients and 48 healthy individuals by Quantimetrix Lipoprint System. In total, 352 T2DM patients before and after treatment and 48 healthy individuals were enrolled in this study. To determine the clinical value of multigene polymorphisms, LDL-C and sdLDL-C on T2DM therapy.
0 kommentar(er)
